3.10
+0.17(+5.80%)
Currency In USD
| Previous Close | 2.93 |
| Open | 2.94 |
| Day High | 3.16 |
| Day Low | 2.92 |
| 52-Week High | 6.14 |
| 52-Week Low | 0.87 |
| Volume | 1.02M |
| Average Volume | 1.1M |
| Market Cap | 313.76M |
| PE | -2.67 |
| EPS | -1.16 |
| Moving Average 50 Days | 2.32 |
| Moving Average 200 Days | 1.71 |
| Change | 0.17 |
If you invested $1000 in Alector, Inc. (ALEC) since IPO date, it would be worth $171.46 as of September 29, 2025 at a share price of $3.1. Whereas If you bought $1000 worth of Alector, Inc. (ALEC) shares 5 years ago, it would be worth $287.17 as of September 29, 2025 at a share price of $3.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
GlobeNewswire Inc.
Sep 16, 2025 12:00 PM GMT
--Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates--SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clin
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PTSOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to cou
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced